Aclarion (NASDAQ:ACON – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Institutional & Insider Ownership
7.5% of Aclarion shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 8.9% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Aclarion and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -10,908.50% | -67.53% | -63.01% |
| NeuroOne Medical Technologies | -29.81% | -74.69% | -44.31% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 0 | 0 | 0 | 1.00 |
| NeuroOne Medical Technologies | 1 | 0 | 2 | 1 | 2.75 |
NeuroOne Medical Technologies has a consensus price target of $2.23, indicating a potential upside of 171.34%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Aclarion.
Volatility and Risk
Aclarion has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Valuation and Earnings
This table compares Aclarion and NeuroOne Medical Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $50,000.00 | 46.07 | -$6.99 million | ($15.00) | -0.18 |
| NeuroOne Medical Technologies | $12.10 million | 3.42 | -$3.61 million | ($0.08) | -10.25 |
NeuroOne Medical Technologies has higher revenue and earnings than Aclarion. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroOne Medical Technologies beats Aclarion on 11 of the 15 factors compared between the two stocks.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
